April 8, 2011
Merck loses market share while attempting to expand the marketing of Gardasil ® for the mature woman . Press SANE Vax Inc. Declares Victory in the campaign to raise awareness about the dangers of Gardasil ” : In a long awaited decision (1), the U.S. FDA ruled against the request to obtain a license Merk Supplemental Biological Applications, supplemental biologics license application (sBLA) – and the drug may not indicate the use of GARDASIL ® [virus vaccine recombinant quadrivalent human papillomavirus (types 6, 11, 16 and 18)] for women aged 27 to 45 years . This was the fourth rejected Merck’s request to expand the use of Gardasil to a broader population of women.
SANE Vax, Inc. welcomes the decision by the FDA . According to Norma Erickson, President of the organization, “This decision marks a major victory for consumers of medical products worldwide. I would like to personally thank the team SaneVax and each of the medical professionals, scientific researchers and educators who helped get the truth behind the development, testing, approval and marketing of this vaccine to the public. ” “The work of SANE team Vax, Inc. has prompted consumers to say enough is enough!” If it is not safe, affordable, necessary or effective, not the need! ”
Leslie Carol Botha, Vice President of Public Relations for SANE Vax, Inc. stated that “it is obvious that the awareness campaign Vax SANE against Gardasil has been effective. We have communicated our concerns to the FDA on several occasions showing peer-reviewed scientific evidence and analysis. At the same time we have written and distributed hundreds of press releases and articles that document not only research, but the harm that Gardasil has caused previously healthy adolescents. We can proudly say that both medical consumers and doctors, as well as the government are paying attention to our concerns. “